Form 4: Vera Therapeutics Officer Sells Shares for Tax

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, sold 2,187 shares of Class A Common Stock to cover tax withholding obligations from RSU vesting.

Summary

• William D. Turner, Chief Regulatory Officer of Vera Therapeutics, Inc. (VERA), disposed of 2,187 shares of Class A Common Stock.
• The sale was executed to satisfy tax withholding obligations incurred upon the vesting of restricted stock units (RSUs).
• This transaction was a mandated 'sell-to-cover' under the Issuer's equity incentive plans and was not a discretionary trade by the reporting person.
• The shares were sold at a weighted-average price of $41.9839, with individual transactions ranging from $41.005 to $42.84 per share.
• Following this transaction, William D. Turner beneficially owns 45,313 shares of Class A Common Stock.
• The trading order for these shares occurred over two business days, from February 23, 2026, to February 24, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and solely for tax purposes related to RSU vesting, which is a routine compensation event.

Positives

• The underlying event of restricted stock unit (RSU) vesting is a positive for the reporting person, representing earned compensation and a retention mechanism.

Negatives

• No direct negatives are associated with this transaction, as it was a non-discretionary sale solely for tax purposes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine mechanism for executives to manage tax liabilities arising from the vesting of equity awards like restricted stock units. Such non-discretionary sales are generally not indicative of an insider's sentiment about the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary event and is unlikely to significantly impact shareholder sentiment or the company's valuation.
• Employees (specifically William D. Turner): The transaction represents the realization of a portion of equity compensation, with the remainder of the vested shares continuing to be held.

Key Dates

Recommendation

The transaction is a non-discretionary 'sell-to-cover' for tax purposes, a routine event for executives receiving equity compensation. It does not reflect a change in the insider's confidence in the company's future and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

Vera Therapeutics, VERA, Insider Trading, Form 4, Restricted Stock Units, RSU, Sell-to-Cover, Tax Withholding, Officer Transaction